Abstract
These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of live, attenuated varicella virus vaccine--VARIVAX--manufactured by Merck and Company, Inc. and licensed in March 1995 for use in healthy persons > or = 12 months of age. In addition to presenting information regarding vaccine, this statement updates previous recommendations concerning the use of varicella zoster immune globulin (VZIG) as prophylaxis against varicella (MMWR 1984; 33:84-90, 95-100).
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Acyclovir / therapeutic use
-
Adolescent
-
Adult
-
Age Distribution
-
Aged
-
Antibodies, Viral / analysis
-
Antiviral Agents / therapeutic use
-
Chickenpox / epidemiology
-
Chickenpox / immunology
-
Chickenpox / prevention & control*
-
Chickenpox / transmission
-
Chickenpox Vaccine
-
Child
-
Child, Preschool
-
Contraindications
-
Cost-Benefit Analysis
-
Cross Infection
-
Drug Storage
-
Female
-
Herpes Zoster / immunology
-
Herpes Zoster / prevention & control
-
Herpes Zoster / transmission
-
Herpesvirus 3, Human* / immunology
-
Humans
-
Immune Sera* / administration & dosage
-
Immune Sera* / adverse effects
-
Immunization, Passive / standards
-
Incidence
-
Infant
-
Infant, Newborn
-
Middle Aged
-
Pregnancy
-
Product Surveillance, Postmarketing
-
Serologic Tests
-
Vaccination / adverse effects
-
Vaccination / economics
-
Vaccination / standards*
-
Vaccines, Attenuated*
-
Viral Vaccines* / administration & dosage
-
Viral Vaccines* / adverse effects
-
Viral Vaccines* / economics
-
Viral Vaccines* / immunology
-
Viral Vaccines* / supply & distribution
Substances
-
Antibodies, Viral
-
Antiviral Agents
-
Chickenpox Vaccine
-
Immune Sera
-
Vaccines, Attenuated
-
Viral Vaccines
-
varicella-zoster immune globulin
-
Acyclovir